AG
CORT icon

Aperio Group’s Corcept Therapeutics CORT Stock Holding History

Aperio Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$752K Buy
28,753
+3,876
+16% +$81.7K ﹤0.01% 1750
2020
Q3 		$433K Sell
24,877
-3,985
-14% -$63.5K ﹤0.01% 1890
2020
Q2 		$485K Buy
28,862
+5,098
+21% +$71.6K ﹤0.01% 1793
2020
Q1 		$283K Buy
23,764
+2,982
+14% +$36.9K ﹤0.01% 1938
2019
Q4 		$251K Sell
20,782
-1,984
-9% -$27.6K ﹤0.01% 2119
2019
Q3 		$322K Buy
22,766
+9,142
+67% +$112K ﹤0.01% 1985
2019
Q2 		$152K Buy
13,624
+2,460
+22% +$27.4K ﹤0.01% 2268
2019
Q1 		$131K Sell
11,164
-11,708
-51% -$145K ﹤0.01% 2222
2018
Q4 		$306K Buy
22,872
+8,351
+58% +$110K ﹤0.01% 1933
2018
Q3 		$203K Sell
14,521
-587
-4% -$8.2K ﹤0.01% 2183
2018
Q2 		$238K Buy
15,108
+109
+0.7% +$1.9K ﹤0.01% 2099
2018
Q1 		$246K Buy
+14,999
New +$278K ﹤0.01% 2043

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Aperio Group's CORT Position: Q4 2020 in Review

Aperio Group increased its Corcept Therapeutics (CORT) stake by 16% in Q4 2020, buying an estimated $81.7K and bringing the position to 28,753 shares worth $752K. The position accounts for ﹤0.01% of the portfolio, ranked #1750.

Aperio Group first reported a position in CORT in Q1 2018 and has held it in 12 quarters since. 226 funds tracked by Wall St. Rank hold CORT as of Q4 2020.

  • Aperio Group held 28,753 shares of Corcept Therapeutics worth $752K as of Q4 2020.
  • Aperio Group bought 3,876 Corcept Therapeutics shares in Q4 2020, an estimated $81.7K.
  • Corcept Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1750 holding.
  • Aperio Group first reported a position in Corcept Therapeutics in Q1 2018 and has held it in 12 quarters since.
  • 226 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.